Merck to Acquire Pandion for ~$1.85B

February 26, 2021 Auto Bot Acquire, M&A, Merck 0

Shots:

  • Merck to acquire all outstanding share of Pandion for $60/share in cash, representing the equity value of ~$1.85B. The transaction is expected to close in H1’21
  • The acquisition will strengthen Merck’s portfolio with the addition of candidates targeting a broad range of autoimmune diseases
  • Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes along with its lead candidate (PT101) intended to treat UC and other autoimmune diseases

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Pandiontx

The post Merck to Acquire Pandion for ~$1.85B first appeared on PharmaShots.